![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1467879
ºÒÀÓ °Ë»ç ½ÃÀå º¸°í¼ : Á¦Ç°, ±¸¸Å ÇüÅÂ, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº°(2024-2032³â)Fertility Test Market Report by Product, Mode of Purchase, Application, End User, and Region 2024-2032 |
¼¼°è ºÒÀÓ °Ë»ç ½ÃÀå ±Ô¸ð´Â 2023³â 5¾ï 5,230¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº 2032³â±îÁö 9¾ï 2,760¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2024-2032³â°£ 5.8%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.
ºÒÀÓ °Ë»ç´Â ºÎºÎÀÇ ÀÓ½ÅÀ» ¹æÇØÇÏ´Â ¹®Á¦¸¦ Áø´ÜÇϱâ À§ÇØ ½ÃÇàµË´Ï´Ù. Ç÷¾× °Ë»ç, °ñ¹Ý ³» °Ë»ç, Á¤¾× ºÐ¼®, ±âÃÊ Ã¼¿Â(BBT) Â÷Æ® ÀÛ¼º, ¼º±³ ÈÄ °Ë»ç, °æÁú(°ñ¹Ý) ÃÊÀ½ÆÄ, Àڱà ³°ü Á¶¿µ¼ú ¶Ç´Â HSG, ÀÚ±Ã°æ °Ë»ç, º¹°°æ °Ë»ç·Î ±¸¼ºµË´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â ½Å·ÚÇÒ ¼ö ÀÖ°í È¿°úÀûÀ̸ç ÀûÀýÇÑ Ä¡·á¹ýÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ Ã¼³» ¼ºº´(STI) °¨¿°À» ¿¹¹æÇÏ´Â È¿°úµµ ÀÖ½À´Ï´Ù. ºÒÀÓ °Ë»ç´Â ÀڱðæºÎ¾ÏÀ̳ª ÀڱðæºÎ ÁÖº¯ÀÇ ºñÁ¤»ó ¼¼Æ÷¸¦ ¹ß°ßÇÏ´Â µ¥µµ µµ¿òÀÌ µË´Ï´Ù. µû¶ó¼ º´¿ø, ÀçÅÃÀÇ·á, ºÒÀÓŬ¸®´Ð µî¿¡¼ ºÒÀӰ˻縦 ½ÃÇàÇϰí ÀÖ½À´Ï´Ù.
³¼ÒÀÇ ¿¡½ºÆ®·Î°Õ °ú´Ù ºÐºñ·Î ÀÎÇÑ ´Ù³¶¼º ³¼Ò ÁõÈıº(PCOS)°ú °°Àº Áúº´ÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀåÀ» ÁÖµµÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, »ýȰ½À°üÀÇ º¯È, ½ºÆ®·¹½º Áõ°¡, ¿îµ¿ ºÎÁ·°ú ½Ä½À°ü º¯È·Î ÀÎÇÑ ºñ¸¸ µîÀ¸·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ºÒÀÓÀ²ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ºÒÀÓ °Ë»çÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´ëÁßµé »çÀÌ¿¡¼ ºÒÀÓÀ» Ä¡·áÇϱâ À§ÇÑ ±â¼úÀûÀ¸·Î Áøº¸µÈ Á¦Ç°ÀÇ Ãâ½Ã´Â ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷µéÀº ¸ðµç ºÒÀÓ °ü·Ã µ¥ÀÌÅ͸¦ Áß¾Ó ÁýÁßÈÇϱâ À§ÇØ ÀӽŠ¹× ¹è¶õ °Ë»ç ŰƮ¸¦ µµÀÔÇϱâ À§ÇÑ ¿¬±¸ °³¹ß Ȱµ¿¿¡ ±¤¹üÀ§ÇÏ°Ô ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ±Þ¼ºÀåÇÏ´Â ÀÇ·á »ê¾÷°ú °áÇÕÇÏ¿© ¾÷°è ÅõÀÚÀڵ鿡°Ô À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ¿Í º°°³·Î, Á¤È®ÇÏ°í »ç¿ëÇϱ⠽¬¿î ºÒÀÓ Ä¡·á ¸ð´ÏÅÍ¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ÀÚ ºÐ¼®¿¡ ÀΰøÁö´É(AI)ÀÇ È°¿ëÀÌ Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global fertility test market size reached US$ 552.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 927.6 Million by 2032, exhibiting a growth rate (CAGR) of 5.8% during 2024-2032.
Fertility tests are performed to diagnose problems that prevent couples from conceiving. They comprise blood tests, pelvic examination, semen analysis, basal body temperature (BBT) charting, post coital test, transvaginal (pelvic) ultrasound exam, hysterosalpingogram or HSG, hysteroscopy, and laparoscopy. They are reliable, valid, and assist in determining a suitable treatment. In addition, they prevent the spread of sexually transmitted infections (STIs) in the body. Fertility tests also help detect cervical cancer and abnormal cells around the cervix. As a result, they are carried out in hospitals, home care, and fertility clinics.
The growing prevalence of diseases, such as polycystic ovary syndrome (PCOS), due to the overproduction of estrogen by the ovaries represents one of the key factors driving the market. Moreover, there is a rise in infertility rates across the globe due to lifestyle changes and increasing stress and obesity, which is caused by a lack of physical exercise and alterations in dietary pattern. This, along with the increasing awareness among the masses about the benefits of fertility tests, is propelling the growth of the market. In addition, the launch of technologically advanced products to treat infertility among the masses is positively influencing the market. Besides this, key market players are extensively investing in research and development (R&D) activities to introduce pregnancy and ovulation test kits for centralizing all fertility-related data. This, coupled with the burgeoning healthcare industry, is offering lucrative growth opportunities to industry investors. Apart from this, there is an increase in the demand for easy-to-use fertility monitors with high accuracy. The rising utilization of artificial intelligence (AI) in sperm analysis is expected to bolster the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global fertility test market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, mode of purchase, application and end user.
Ovulation Prediction Kits
Fertility Monitors
Male Fertility Testing Products
OTC-based
Prescription-based
Female Fertility Testing
Male Fertility Testing
Hospitals
Home Care Settings
Fertility Clinics
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AdvaCare Pharma, Ava AG, Babystart Ltd. (Snowden Healthcare), Church & Dwight Co. Inc., Fairhaven Health LLC, Geratherm Medical AG, Prestige Consumer Healthcare Inc., Quidel Corporation, UEBE Medical GmbH, Valley Electronics AG and viO HealthTech Limited.